Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio

被引:296
作者
Bhatti, Imran [1 ]
Peacock, Oliver [2 ]
Lloyd, Gareth [2 ]
Larvin, Michael [1 ]
Hall, Richard I. [2 ]
机构
[1] Univ Nottingham, Sch Grad Entry Med & Hlth, Div Surg, Derby City Gen Hosp, Derby DE22 3DT, England
[2] Derby City Gen Hosp, Dept Surg, Derby DE22 3DT, England
关键词
Preoperative markers; Neutrophil-lymphocyte ratio; Prognosis; Pancreatic cancer; COLONY-STIMULATING FACTOR; TUMOR NECROSIS FACTOR; CIRCULATING NUMBERS; LONG-TERM; CANCER; KINETICS; SURVIVAL; CARCINOMA; CYTOKINES; HEAD;
D O I
10.1016/j.amjsurg.2009.08.041
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: The objective of this study was to investigate whether the preoperative hematologic markers, the platelet-lymphocyte ratio (PLR), or the neutrophil-lymphocyte ratio (NLR) ratio are significant prognostic indicators in resected pancreatic ductal adenocarcinoma. METHODS: A total of 84 patients undergoing pancreatoduodenectomy for pancreatic ductal adenocarcinoma over a 10-year period were identified from a retrospectively maintained database. RESULTS: The preoperative NLR was found to be a significant prognostic marker (P=.023), whereas PLR had no significant relationship with survival (P=.642) using univariate Cox survival analysis. The median overall survival in patients with an NLR of <= 3.0 (n = 55) was 13.7, 17.0 months in those with an NLR of 3.0 to 4.0 (n = 17) and 5.9 months in patients with a value of >4.0 (n = 12) (log rank, P=.016). The NLR retained its significance on multivariate analysis (P=.039) along with resection margin status (P=.001). CONCLUSION: The preoperative NLR represents a significant independent prognostic indicator in patients with resected pancreatic ductal adenocarcinoma, whereas PLR does not. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:197 / 203
页数:7
相关论文
共 40 条
  • [1] KINETICS OF HUMAN HEMATOPOIETIC-CELLS AFTER INVIVO ADMINISTRATION OF GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR
    AGLIETTA, M
    PIACIBELLO, W
    SANAVIO, F
    STACCHINI, A
    APRA, F
    SCHENA, M
    MOSSETTI, C
    CARNINO, F
    CALIGARISCAPPIO, F
    GAVOSTO, F
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1989, 83 (02) : 551 - 557
  • [2] Current standards of surgery for pancreatic cancer
    Alexakis, N
    Halloran, C
    Raraty, M
    Ghaneh, P
    Sutton, R
    Neoptolemos, JP
    [J]. BRITISH JOURNAL OF SURGERY, 2004, 91 (11) : 1410 - 1427
  • [3] Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis
    Alexandrakis, MG
    Passam, FH
    Moschandrea, IA
    Christophoridou, AV
    Pappa, CA
    Coulocheri, SA
    Kyriakou, DS
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2003, 26 (02): : 135 - 140
  • [4] Influence of surgical resection and post-operative complications on survival following adjuvant treatment for pancreatic cancer in the ESPAC-1 randomized controlled trial
    Bassi, C
    Stocken, DD
    Olah, A
    Friess, H
    Buckels, J
    Hickey, H
    Dervenis, C
    Dunn, JA
    Deakin, M
    Carter, R
    Ghaneh, P
    Neoptolemos, JP
    Büchler, MW
    [J]. DIGESTIVE SURGERY, 2005, 22 (05) : 353 - 363
  • [5] Tumor-associated transforming growth factor-β and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients
    Bellone, G
    Turletti, A
    Artusio, E
    Mareschi, K
    Carbone, A
    Tibaudi, D
    Robecchi, A
    Emanuelli, G
    Rodeck, U
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (02) : 537 - 547
  • [6] Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: implications for survival
    Bellone, G
    Smirne, C
    Mauri, FA
    Tonel, E
    Carbone, A
    Buffolino, A
    Dughera, L
    Robecchi, A
    Pirisi, M
    Emanuelli, G
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (06) : 684 - 698
  • [7] Berger AC, 2004, AM SURGEON, V70, P235
  • [8] Survival of patients with periampullary carcinoma is predicted by lymph node 8a but not by lymph node 16b1 status
    Connor, S
    Bosonnet, L
    Ghaneh, P
    Alexakis, N
    Hartley, M
    Campbell, F
    Sutton, R
    Neoptolemos, JP
    [J]. BRITISH JOURNAL OF SURGERY, 2004, 91 (12) : 1592 - 1599
  • [9] Inflammation and cancer
    Coussens, LM
    Werb, Z
    [J]. NATURE, 2002, 420 (6917) : 860 - 867
  • [10] Monocytes and neutrophils as 'bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma - results from a randomised phase II trial
    Donskov, F
    Hokland, M
    Marcussen, N
    Madsen, HHT
    von der Maase, H
    [J]. BRITISH JOURNAL OF CANCER, 2006, 94 (02) : 218 - 226